資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/32520
|
| 標題: | Clinical Benefit of Empiric High-Dose Levofloxacin Therapy for Adults With Community-onset plates Enterobacteriaceae Bacteremia |
| 作者: | Lee, Ching-Chi
Yang, Chao-Yung
Lee, Chung-Hsun
Hsieh, Chih-Chia
Hong, Ming-Yuan
Hung-Jen Tang(湯宏仁)
Ko, Wen-Chien |
| 貢獻者: | Tainan Sin Lau Hosp, Dept Adult Crit Care Med
Chang Jung Christian Univ, Coll Hlth Sci, Grad Inst Med Sci
Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Emergency Med
Natl Cheng Kung Univ, Coll Med, Dept Med
Chi Mei Med Ctr, Dept Med
Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med |
| 關鍵字: | bacteremia
defervescence
empiric therapy
Enterobacteriaceae
high-dose
levofloxacin |
| 日期: | 2019-10 |
| 上傳時間: | 2020-07-29 13:48:19 (UTC+8) |
| 出版者: | ELSEVIER |
| 摘要: | Purpose: Levofloxacin is commonly prescribed to treat varied community-acquired gram-negative infections; knowledge of the therapeutic efficacies of high-dose (HD) administration is helpful to improve patient care. Methods: In this 6-year cohort, adults with community-onset Enterobacteriaceae bacteremia were retrospectively studied in 2 hospitals. To overcome the confounding factors in the dosage choice of empiric administration, patients receiving empiric intravenous HD (750 mg/d) therapy were matched with those receiving the conventional dose (CD; 500 mg/d) by using individual propensity scores, calculated by the independent predictors of 30-day crude mortality. Findings: Initially, more patients with critical illness (Pitt bacteremia score [PBS] >= 4) at bacteremia onset and comorbid malignancies and the higher 15- and 30-day mortality rate were recorded in 136 patients receiving HD therapy, compared to 103 receiving CD therapy. After appropriate matching, differences in patient demographic and clinical characteristics between the HD (n = 103) and CD (n = 103) groups were nonsignificant. Consequently, crude mortality rates at 3, 15, or 30 days after onset of bacteremia did not differ. However, the period of time to defervescence, total intravenous antimicrobial administration, and hospital stay was shorter in the HD group than in the CD group. Similarly, regardless if patients had more critical illness (PBS >= 2) or stabilized illness (PBS <2), the advantage of empiric HD therapy on defervescence remained significant. Within 60 days after discontinuation of intravenous levofloxacin therapy, the proportion of recurrent bacteremia, posttreatment overall infections, and posttreatment crude mortality was similar between the HD and CD groups. (C) 2019 Published by Elsevier Inc. |
| 關聯: | Clinical the rapeutics, v.41, n.10, pp.1996-2007 |
| 顯示於類別: | [保健營養系(所) ] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 1154 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
